LSE:HCM (HUTCHMED)
About HCM
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Its reportable segments include the innovation platform and commercial platform. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The commercial platform includes a prescription drugs business and a consumer health business for over-the-counter drugs.
HUTCHMED (LSE: HCM) Latest News
Investing Articles
Should You Buy Hikma Pharmaceuticals Plc, Circassia Pharmaceuticals PLC & Hutchison China MediTech Limited On Today’s News?
Investing Articles
Why GlaxoSmithKline plc And Hutchison China MediTech Limited Are A Perfect Pairing
Investing Articles
Should You Follow Directors Buying At Monitise Plc, Hutchison China MediTech Limited And Tungsten Corp PLC?
❮2